Tempus Unveils Tempus O, a Platform to Structure and Annotate Clinical Data at Scale Print E-mail
By GLOBE NEWSWIRE   
Thursday, 07 December 2017 06:22

CHICAGO, Dec. 07, 2017 (GLOBE NEWSWIRE)

CHICAGO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of + '/park.js">' molecular and clinical data today announced the launch of + '<\/script>' Tempus O, a groundbreaking system that collects, structures and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the + 'Skenzor6' treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com.

Tempus:
Clo Ewing 
clo@tempus.com

Primary Logo




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter

BMR:1